FDA clears Alzheimer’s blood test: a game changer for biomarker-driven trials

AbbVie submitted an NDA to the FDA following Ph3 data of Tavapadon targeting Parkinson’s

BMS granted FDA Fast Track Designation for BMS-986446 - an anti-microtubule binding region tau antibody currently in Ph2 targeting Alzheimer’s

C2N Diagnostics submitted regulatory filing to the FDA for their Alzheimer’s blood test

Herantis Pharma announced positive topline Ph1b data evaluation HER-096 targeting PD

Prasinezumab: Advancing Towards the First Disease Modifying Treatment for Parkinson’s Disease

Prasinezumab: Advancing Towards the First Disease Modifying Treatment for Parkinson’s Disease

By | 17 September 2025

Demonstrating clinical potential of Prasinezumab to delay motor progression, highlighting meaningful functional benefit for patients
Outlining α-synuclein targeting mechanism with supporting biomarker evidence to validate biological activity and translational relevance
Exploring future Phase III directions and beyond to position Prasinezumab as a first-in-class disease-modifying therapy

VIRTUAL